Abstract: Disclosed is a process for preparing agents containing virus-inactivated vitamin K-dependent plasma components as well as protein C, protein S, factors II, VII, IX and/or X as well as combinations thereof, such as, for example, PPSB preparations, wherein a source containing these components is subjected to a appropriate separation procedures, especially by using membrane-chromatographic methods.
Abstract: The present invention relates to a process for the preparation of a solution comprising a substantially pure isoform of AT-III, said process comprising separating the isoform AT-III&agr; from AT-III&bgr; on a calcium hydroxyphosphate-based adsorbent.
Abstract: Filtration methods comprise virus-filtering a solution containing a least one macromolecule. The total salt content of the solution for virus-filtering is within the range of from about 0.2 M up to saturation with the salt. Salts that can be used in the filtering methods include sodium chloride, potassium chloride, sodium acetate, sodium citrate, sodium phosphate, potassium dyhydrophosphate and combinations thereof.
Type:
Application
Filed:
November 26, 2002
Publication date:
October 9, 2003
Applicant:
Octapharma AG, a Corporation of Switzerland
Abstract: A method for the inactivation of viruses, in particular those having no lipid coats, in protein-containing compositions from blood, blood plasma or similar natural sources by treating said source, simultaneously or succesively, with an effective amount of dialkyl or trialkyl phosphates and optionally surfactants at an elevated temperature in the range of from 55° C. to 67° C. for five hours to 30 hours.
Type:
Grant
Filed:
September 28, 1995
Date of Patent:
March 4, 2003
Assignee:
Octapharma AG
Inventors:
Monika Stadler, Horst Schwinn, Djuro Josic, Werner Gehringer, Frederic Bal
Abstract: The present invention relates to methods for purification of antithrombin-III (AT-III) by precipitation of impurities. The said methods comprise (a) adding, to a solution comprising antithrombin-III, a saccharide and citrate, in an amount sufficient for impurities to precipitate while antithrombin-III essentially remains in solution; (b) allowing impurities to precipitate; and (c) removing the precipitated impurities, thereby obtaining a solution comprising purified antithrombin-III. The invention also relates to pharmaceutical compositions, obtainable by the said methods, comprising purified antithrombin-III, as well as to reconstituted pharmaceutical compositions essentially free from visible particles.
Abstract: A universally applicable blood plasma obtainable by a process comprising the steps of mixing blood or blood plasma of blood groups A and B optionally blood or blood plasma of blood group AB without admixing substantial amounts of blood or blood plasma derived from blood group 0.
Abstract: Disclosed is a process for preparing agents containing virus-inactivated vitamin K-dependent plasma components as well as protein C, protein S, factors II, VII, IX and/or X as well as combinations thereof, such as, for example, PPSB preparations, wherein a source containing these components is subjected to a appropriate separation procedures, especially by using membrane-chromatographic methods.
Abstract: The invention concerns a method for preparing native collagen, comprising pretreatment of the collagen in a mixer with double transverse cutters equipped with a system controlling agitating and shearing velocity and a thermostat, and a subsequent step of sterilizing the collagen in liquid medium. The invention also concerns a sterile collagen, in particular a collagen mostly of type I, in native state and in particular pharmaceutical and/or parapharmaceutical and/or medico-surgical and/or ophthalmologic and/or cosmetic compositions and applications thereof.
Abstract: A method for reduction of the viral infectiousness of potentially infectious material, such as human or animal body fluids or fractions derived therefrom from which biologically active substances can be isolated, wherein the infectiousness is due to non-lipid-coated viruses characterized in thatsaid potentially infectious material for the isolation of said biologically active substances is treated witha hydrophobic phase which is essentially insoluble in water and is capable of forming a two-phase system with said potentially infectious material, andsaid hydrophobic phase is separated from the potentially infectious material thus treated.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
October 24, 2000
Assignee:
Octapharma AG
Inventors:
Lothar Biesert, Horst Schwinn, Wolfgang Marguerre
Abstract: The method for the aptitude testing of protein fractions containing factor VIII the further processing of which comprises a pasteurizing step is performed in such a way that the starting material is examined for fragments within a range of from 20 to 50 kD. Fragments of factor VIII within this range evidently cause inhibitor formations in patients pretreated with factor VIII. Batches contaminated with such fragments can also be utilized, i.e., for the preparation of a high purity virus-free factor VIII by size exclusion chromatography on hydrophilic materials.
Type:
Grant
Filed:
January 7, 1999
Date of Patent:
May 2, 2000
Assignee:
Octapharma AG
Inventors:
Andrea Buchacher, Monika Stadler, DJuro Josic
Abstract: A method for reduction of the viral infectiousness of potentially infectious material, such as human or animal body fluids or fractions derived therefrom from which biologically active substances can be isolated, wherein the infectiousness is due to non-lipid-coated viruses characterized in thatsaid potentially infectious material for the isolation of said biologically active substances is treated witha hydrophobic phase which is essentially insoluble in water and is capable of forming a two-phase system with said potentially infectious material, andsaid hydrophobic phase is separated from the potentially infectious material thus treated.
Type:
Grant
Filed:
February 19, 1998
Date of Patent:
December 28, 1999
Assignee:
Octapharma AG
Inventors:
Wolfgang Marguerre, Horst Schwinn, Lothar Biesert
Abstract: A process for the preparation of factor IX from a biological source by chromatography involves prior treatment with ammonium sulfate as a protein precipitant at a concentration of from 1.5-2.3 mol/l.
Type:
Grant
Filed:
November 26, 1997
Date of Patent:
July 6, 1999
Assignee:
Octapharma AG
Inventors:
Djuro Josic, Lutz Hoffer, Frank Morfeld
Abstract: Described is an economical process for the recovery of factor VIII from blood plasma or cryoprecipitate. In the process, anion exchanger chromatography is conducted using a separating material based on carriers containing hydroxyl groups, the surfaces of which carriers have been coated with covalently boded polymers. The polymers contain repeating units represented by formula (I).
Abstract: This invention describes a process for preparing virus-inactivated immunoglobulin solutions suitable for intra-venous application, characterized in that the immunoglobulin is treated with non-ionic surfactants which subsequently are removed by solid-phase extraction on hydrophobic materials.
Abstract: A stable, injectable solution containing factor VIII suitable for the treatment of humans, natural or synthetic disaccharides, preferably saccharose, in concentrations of from 0.1 to 0.65 mol/1, and one or more amino acids in concentrations of from 0.1 to 1.0 mol/1. A process for preparing same and the use of natural or synthetic disaccharides, preferably saccharose, and one or more amino acids for stabilizing factor VIII.